PTGX
Protagonist Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
10.64
P/S
142.67
EV/EBITDA
-45.05
DCF Value
$-8.63
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-343.6%
Net Margin
-282.8%
ROE
-19.9%
ROA
-19.4%
ROIC
-25.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.4M | $-44.4M | $-0.69 |
| FY 2025 | $46.0M | $-130.1M | $-2.05 |
| Q3 2025 | $4.7M | $-39.3M | $-0.62 |
| Q2 2025 | $5.5M | $-34.8M | $-0.55 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.11
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.